Innate Pharma (IPHA) Competitors $1.88 -0.02 (-1.06%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends IPHA vs. NUVB, CRVS, ORIC, ALMS, SLN, AURA, VERV, ARCT, LRMR, and KALVShould you be buying Innate Pharma stock or one of its competitors? The main competitors of Innate Pharma include Nuvation Bio (NUVB), Corvus Pharmaceuticals (CRVS), ORIC Pharmaceuticals (ORIC), Alumis (ALMS), Silence Therapeutics (SLN), Aura Biosciences (AURA), Verve Therapeutics (VERV), Arcturus Therapeutics (ARCT), Larimar Therapeutics (LRMR), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry. Innate Pharma vs. Nuvation Bio Corvus Pharmaceuticals ORIC Pharmaceuticals Alumis Silence Therapeutics Aura Biosciences Verve Therapeutics Arcturus Therapeutics Larimar Therapeutics KalVista Pharmaceuticals Innate Pharma (NASDAQ:IPHA) and Nuvation Bio (NYSE:NUVB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, community ranking, profitability and risk. Does the MarketBeat Community favor IPHA or NUVB? Innate Pharma received 1 more outperform votes than Nuvation Bio when rated by MarketBeat users. However, 77.36% of users gave Nuvation Bio an outperform vote while only 56.76% of users gave Innate Pharma an outperform vote. CompanyUnderperformOutperformInnate PharmaOutperform Votes4256.76% Underperform Votes3243.24% Nuvation BioOutperform Votes4177.36% Underperform Votes1222.64% Which has more risk & volatility, IPHA or NUVB? Innate Pharma has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Do institutionals & insiders believe in IPHA or NUVB? 0.2% of Innate Pharma shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by company insiders. Comparatively, 5.1% of Nuvation Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is IPHA or NUVB more profitable? Innate Pharma's return on equity of 0.00% beat Nuvation Bio's return on equity.Company Net Margins Return on Equity Return on Assets Innate PharmaN/A N/A N/A Nuvation Bio N/A -16.57%-13.93% Which has stronger valuation and earnings, IPHA or NUVB? Innate Pharma has higher revenue and earnings than Nuvation Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInnate Pharma$66.71M2.28-$8.19MN/AN/ANuvation BioN/AN/A-$75.80M-$2.11-1.09 Do analysts prefer IPHA or NUVB? Innate Pharma currently has a consensus price target of $11.50, suggesting a potential upside of 513.33%. Nuvation Bio has a consensus price target of $6.40, suggesting a potential upside of 178.26%. Given Innate Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Innate Pharma is more favorable than Nuvation Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innate Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Nuvation Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to IPHA or NUVB? In the previous week, Nuvation Bio had 2 more articles in the media than Innate Pharma. MarketBeat recorded 3 mentions for Nuvation Bio and 1 mentions for Innate Pharma. Nuvation Bio's average media sentiment score of 0.77 beat Innate Pharma's score of 0.00 indicating that Nuvation Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innate Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvation Bio 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryInnate Pharma beats Nuvation Bio on 9 of the 15 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPHA vs. The Competition Export to ExcelMetricInnate PharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$151.82M$3.16B$5.40B$8.53BDividend YieldN/A1.77%5.13%4.14%P/E RatioN/A12.18115.5615.18Price / Sales2.28332.351,484.3492.77Price / CashN/A148.6339.6634.07Price / Book2.724.024.665.02Net Income-$8.19M-$42.25M$119.06M$225.46M7 Day Performance4.17%8.06%0.80%0.37%1 Month Performance-13.61%8.71%5.65%3.57%1 Year Performance-15.92%32.10%36.76%29.44% Innate Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPHAInnate Pharma2.8052 of 5 stars$1.88-1.1%$11.50+513.3%-13.6%$151.82M$66.71M0.00220Gap DownNUVBNuvation Bio3.8174 of 5 stars$2.27+2.7%$6.40+181.9%+98.3%$561.08M$1.44M-1.0860Upcoming EarningsCRVSCorvus Pharmaceuticals1.5974 of 5 stars$8.90+7.1%$10.83+21.7%+671.2%$556.70MN/A-19.7830Upcoming EarningsAnalyst DowngradeShort Interest ↑High Trading VolumeORICORIC Pharmaceuticals4.2103 of 5 stars$8.25+1.2%$18.00+118.2%+43.2%$556.23MN/A-4.7180Upcoming EarningsAnalyst ForecastNews CoverageALMSAlumisN/A$11.84-0.5%$28.00+136.5%N/A$552.09MN/A0.00N/AAnalyst ForecastNews CoverageSLNSilence Therapeutics2.7473 of 5 stars$18.26+1.0%$57.20+213.3%+104.2%$546.52M$31.55M-14.97100AURAAura Biosciences3.9407 of 5 stars$11.02+0.9%$23.00+108.7%+13.2%$545.96MN/A-6.1650Short Interest ↓VERVVerve Therapeutics2.3276 of 5 stars$6.32+5.9%$26.00+311.4%-49.5%$534.80M$11.76M-2.44110Upcoming EarningsARCTArcturus Therapeutics2.6045 of 5 stars$19.80+4.5%$71.40+260.6%-4.1%$533.25M$147.03M-7.70180Upcoming EarningsNews CoverageGap UpLRMRLarimar Therapeutics2.8618 of 5 stars$8.34+4.1%$20.43+144.9%+169.7%$532.18MN/A-7.4530Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageKALVKalVista Pharmaceuticals3.3891 of 5 stars$12.12+3.8%$26.00+114.5%+21.0%$511.32MN/A-3.43150 Related Companies and Tools Related Companies NUVB Alternatives CRVS Alternatives ORIC Alternatives ALMS Alternatives SLN Alternatives AURA Alternatives VERV Alternatives ARCT Alternatives LRMR Alternatives KALV Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IPHA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
